BioMarin Pharmaceutical Statistics
Total Valuation
BMRN has a market cap or net worth of $11.03 billion. The enterprise value is $10.36 billion.
| Market Cap | 11.03B |
| Enterprise Value | 10.36B |
Important Dates
The next estimated earnings date is Monday, August 4, 2025, after market close.
| Earnings Date | Aug 4, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
BMRN has 191.78 million shares outstanding. The number of shares has increased by 1.66% in one year.
| Current Share Class | 191.78M |
| Shares Outstanding | 191.78M |
| Shares Change (YoY) | +1.66% |
| Shares Change (QoQ) | -0.05% |
| Owned by Insiders (%) | 0.75% |
| Owned by Institutions (%) | 92.25% |
| Float | 179.36M |
Valuation Ratios
The trailing PE ratio is 21.25 and the forward PE ratio is 13.02. BMRN's PEG ratio is 0.70.
| PE Ratio | 21.25 |
| Forward PE | 13.02 |
| PS Ratio | 3.71 |
| Forward PS | 3.37 |
| PB Ratio | 1.90 |
| P/TBV Ratio | 2.06 |
| P/FCF Ratio | 17.67 |
| P/OCF Ratio | 15.75 |
| PEG Ratio | 0.70 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 12.84, with an EV/FCF ratio of 16.59.
| EV / Earnings | 19.77 |
| EV / Sales | 3.51 |
| EV / EBITDA | 12.84 |
| EV / EBIT | 14.48 |
| EV / FCF | 16.59 |
Financial Position
The company has a current ratio of 5.52, with a Debt / Equity ratio of 0.10.
| Current Ratio | 5.52 |
| Quick Ratio | 3.20 |
| Debt / Equity | 0.10 |
| Debt / EBITDA | 0.73 |
| Debt / FCF | 0.96 |
| Interest Coverage | 59.71 |
Financial Efficiency
Return on equity (ROE) is 9.64% and return on invested capital (ROIC) is 7.12%.
| Return on Equity (ROE) | 9.64% |
| Return on Assets (ROA) | 6.38% |
| Return on Invested Capital (ROIC) | 7.12% |
| Return on Capital Employed (ROCE) | 10.98% |
| Revenue Per Employee | $970,469 |
| Profits Per Employee | $172,330 |
| Employee Count | 3,040 |
| Asset Turnover | 0.42 |
| Inventory Turnover | 0.46 |
Taxes
In the past 12 months, BMRN has paid $150.42 million in taxes.
| Income Tax | 150.42M |
| Effective Tax Rate | 22.31% |
Stock Price Statistics
The stock price has decreased by -30.07% in the last 52 weeks. The beta is 0.17, so BMRN's price volatility has been lower than the market average.
| Beta (5Y) | 0.17 |
| 52-Week Price Change | -30.07% |
| 50-Day Moving Average | 58.25 |
| 200-Day Moving Average | 64.59 |
| Relative Strength Index (RSI) | 55.64 |
| Average Volume (20 Days) | 2,234,928 |
Short Selling Information
The latest short interest is 4.42 million, so 2.30% of the outstanding shares have been sold short.
| Short Interest | 4.42M |
| Short Previous Month | 4.15M |
| Short % of Shares Out | 2.30% |
| Short % of Float | 2.46% |
| Short Ratio (days to cover) | 1.85 |
Income Statement
In the last 12 months, BMRN had revenue of $2.95 billion and earned $523.88 million in profits. Earnings per share was $2.71.
| Revenue | 2.95B |
| Gross Profit | 2.39B |
| Operating Income | 715.47M |
| Pretax Income | 298.68M |
| Net Income | 523.88M |
| EBITDA | 806.62M |
| EBIT | 715.47M |
| Earnings Per Share (EPS) | $2.71 |
Balance Sheet
The company has $1.27 billion in cash and $601.96 million in debt, giving a net cash position of $670.38 million or $3.50 per share.
| Cash & Cash Equivalents | 1.27B |
| Total Debt | 601.96M |
| Net Cash | 670.38M |
| Net Cash Per Share | $3.50 |
| Equity (Book Value) | 5.79B |
| Book Value Per Share | 30.21 |
| Working Capital | 2.84B |
Cash Flow
In the last 12 months, operating cash flow was $700.26 million and capital expenditures -$76.09 million, giving a free cash flow of $624.18 million.
| Operating Cash Flow | 700.26M |
| Capital Expenditures | -76.09M |
| Free Cash Flow | 624.18M |
| FCF Per Share | $3.25 |
Margins
Gross margin is 81.01%, with operating and profit margins of 24.25% and 17.76%.
| Gross Margin | 81.01% |
| Operating Margin | 24.25% |
| Pretax Margin | 22.86% |
| Profit Margin | 17.76% |
| EBITDA Margin | 27.34% |
| EBIT Margin | 24.25% |
| FCF Margin | 21.16% |
Dividends & Yields
BMRN does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1.65% |
| Shareholder Yield | -1.65% |
| Earnings Yield | 4.75% |
| FCF Yield | 5.66% |
Analyst Forecast
The average price target for BMRN is $93.43, which is 62.49% higher than the current price. The consensus rating is "Buy".
| Price Target | $93.43 |
| Price Target Difference | 62.49% |
| Analyst Consensus | Buy |
| Analyst Count | 22 |
| Revenue Growth Forecast (5Y) | 7.84% |
| EPS Growth Forecast (5Y) | 28.07% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
BMRN has an Altman Z-Score of 7.57 and a Piotroski F-Score of 7.
| Altman Z-Score | 7.57 |
| Piotroski F-Score | 7 |